4ZU Stock Chart & Stats
€5.10
€0.00(0.00%)
At close: 4:00 PM EST
€5.10
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€5.10 - €5.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€796.00
Enterprise Value€54.77
Total Cash (Recent Filing)€3.20M
Total Debt (Recent Filing)€39.65M
Price to Earnings (P/E)―
Beta0.52
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,522,702
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.17
Price to Sales (P/S)573.04
P/FCF Ratio0.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBiora presented a summary of BT-600 Phase 1 clinical trial data at the American College of Gastroenterology meeting, following the initial disclosure of positive results.
Product DevelopmentBiora's second primary program, Biojet, continues to make progress with the announcement of a smaller BioJet device, which increases payload capacity while decreasing its overall size.
Product PotentialKOL event highlights BT-600 Phase 1 data and reinforces NaviCap's potential in UC.
Strategic FocusBiora has disclosed a strategic realignment of its resources to focus on its BioJet program to expedite near-term results needed by Big Pharma collaborators to progress licensing and partnering discussions.
Bears Say
EarningsBiora announced 3Q24 results, posting EPS of ($5.04) compared to analyst's estimate of ($4.20) and consensus estimate of ($3.85).
Financial PerformanceBiora's financial results show a larger loss than both analyst and consensus estimates, which may impact investor confidence.
Biora Therapeutics News
4ZU FAQ
What was Biora Therapeutics’s price range in the past 12 months?
Biora Therapeutics lowest stock price was €5.10 and its highest was €5.40 in the past 12 months.
What is Biora Therapeutics’s market cap?
Biora Therapeutics’s market cap is €796.00.
When is Biora Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Biora Therapeutics’s earnings last quarter?
Currently, no data Available
Is Biora Therapeutics overvalued?
According to Wall Street analysts Biora Therapeutics’s price is currently Overvalued.
Does Biora Therapeutics pay dividends?
Biora Therapeutics does not currently pay dividends.
What is Biora Therapeutics’s EPS estimate?
Biora Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biora Therapeutics have?
Biora Therapeutics has 4,522,702 shares outstanding.
What happened to Biora Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biora Therapeutics?
Currently, no hedge funds are holding shares in DE:4ZU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biora Therapeutics
Biora Therapeutics, Inc. operates as a biotechnology company, primarily focused on developing innovative oral biotherapeutics. The company's core efforts include: 1. Targeted Therapeutics Program: This initiative employs an advanced, ingestible smart capsule engineered for the precise administration of medications directly within the gastrointestinal (GI) tract. The aim is to enhance the efficacy of treatments for inflammatory bowel diseases. 2. Systemic Therapeutics Program: Utilizing an orally delivered capsule, this program offers a non-invasive method for delivering biotherapeutics. These are released straight into the intestinal mucosa, facilitating improved absorption into the bloodstream and broader systemic effects, thereby eliminating the need for injections. Additionally, Biora Therapeutics is engaged in creating diagnostic devices. These tools are designed to evaluate the characteristics of the GI tract and identify various digestive conditions, such as small intestine bacterial overgrowth (SIBO), by enabling diagnosis directly where the disease manifests. Established in 2010, the company previously operated under the name Progenity, Inc. It rebranded as Biora Therapeutics, Inc. in April 2022 to underscore its strategic focus on its therapeutic product pipeline. Its headquarters are situated in San Diego, California.